Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Vet Pharmacol Ther ; 41(1): e16-e21, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28815733

ABSTRACT

This study was conducted to compare the pharmacokinetic profiles of conventional (Fungizone® ) and liposomal amphotericin B (AmBisome® ) formulations in order to predict their therapeutic properties, and evaluate their potential differences in veterinary treatment. For this purpose, twelve healthy mixed breed dogs received both drugs at a dose of 0.6 mg/kg by intravenous infusion over a 4-min period in a total volume of 40 ml. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 and 96 hr after dosing, and concentrations of drug in plasma were determined by high-performance liquid chromatography (HPLC). Pharmacokinetics was described by a two-compartment model. Although both formulations were administered at the same doses (0.6 mg/kg), the plasma pharmacokinetics of liposomal amphotericin B differed significantly from those of amphotericin B deoxycholate in healthy dogs (p < .05). Liposomal amphotericin B showed markedly higher peak plasma concentrations (approximately ninefold greater) and higher area under the plasma concentration curve values (approximately 14-fold higher) compared to conventional formulation. It is concluded that AmBisome® reached higher plasma concentration and lower distribution volume and had a longer half-life compared to Fungizone® , and therefore, AmBisome® is reported to be an appropriate and effective choice for the treatment of systemic mycotic infections in dogs.


Subject(s)
Amphotericin B/pharmacokinetics , Antifungal Agents/pharmacokinetics , Amphotericin B/administration & dosage , Amphotericin B/blood , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/blood , Dogs , Drug Compounding/veterinary , Infusions, Intravenous/veterinary , Male
2.
J Obstet Gynaecol ; 31(1): 54-8, 2011.
Article in English | MEDLINE | ID: mdl-21280995

ABSTRACT

We aimed to compare the accuracy of transvaginal sonography (TVS), saline infusion sonohysterography (SIS) and hysteroscopy (HS) for uterine pathologies among infertile women. A total of 346 patients were selected for operative hysteroscopy, following SIS after TVS. SIS was performed with a Cook Soft 500 IVF catheter. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated to compare the accuracy of TVS, SIS and hysteroscopy for uterine abnormalities. SIS showed a sensitivity of 87%, specificity of 100% and PPV of 100% for endometrial hyperplasia, and a sensitivity and NPV of 100% for polypoid lesions. For submucosal myoma SIS showed a sensitivity of 99% with PPV of 96%. Hysteroscopy had a sensitivity, specificity, PPV and NPV of 98%, 83%, 96% and 91%, respectively for overall uterine pathologies. Finally, SIS seems to be superior to TVS, for uterine pathologies, with respect to hysteroscopy as the gold standard.


Subject(s)
Hysteroscopy/standards , Infertility, Female/diagnostic imaging , Infertility, Female/pathology , Ultrasonography/standards , Adult , Biopsy , Female , Humans , Hysteroscopy/methods , Leiomyoma/diagnostic imaging , Leiomyoma/pathology , Menorrhagia/diagnostic imaging , Menorrhagia/pathology , Polyps/diagnostic imaging , Polyps/pathology , Predictive Value of Tests , Pregnancy , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Sodium Chloride , Ultrasonography/methods , Uterine Diseases/diagnostic imaging , Uterine Diseases/pathology , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/pathology , Vagina
3.
Maturitas ; 58(3): 236-40, 2007 Nov 20.
Article in English | MEDLINE | ID: mdl-17920792

ABSTRACT

OBJECTIVE: Sexuality is a basic human function that can affect general well-being and overall life quality. The aim of this study was to assess the level of knowledge on and attitude toward sexuality of a subgroup of Turkish women. METHODS: A cross-sectional survey including 1007 women was carried out concurrently in gynecology and urology outpatient clinics of Gazi University Faculty of Medicine, Turkey, between January 2003 and December 2003. A self-created questionnaire for data collection was administered to the participants, which addressed questions concerning their sexual life, sexual problems and attitudes towards sexuality. Statistical package for the social sciences (SPSS) was used for the data analysis of the study (SPSS ver. 11.0 Inc. Chicago, IL, USA). RESULTS: The data included 1007 patients aged 14-77 (mean: 35.6 +/- 11.1). Among the women assessed, 90.2% were married, 79.8% were premenopausal and 77.1% were currently sexually active. 68.7% entered sexual intercourse 1-2 times per week, while 28.5% had an average of 3-4. 77.8% were aware of experiencing an orgasm and 74.7% had at least one orgasm. Only 21.4% of all women had an orgasm during each sexual intercourse. 2.2% of those who had never experienced an orgasm concurrently applied to a medical center. The average age of first intercourse was 21.3 +/- 4.1 years. CONCLUSIONS: Because there is no national data on sexual health in Turkey, analysis and evaluation of the severity of the problem, and alternatives for international comparisons are not possible. In our opinion, this study presents a valuable perception into the current sexual behavior of Turkish women.


Subject(s)
Health Knowledge, Attitudes, Practice , Sexuality , Adolescent , Adult , Aged , Cross-Sectional Studies , Female , Humans , Middle Aged , Surveys and Questionnaires , Turkey , Women's Health
4.
Phys Chem Chem Phys ; 9(15): 1764-73, 2007 Apr 21.
Article in English | MEDLINE | ID: mdl-17415487

ABSTRACT

The melting behaviour and transport properties of straight chain alkanes mono- and difunctionalized with phosphonic acid groups have been investigated as a function of their length. The increase of melting temperature and decrease of proton conductivity with increasing chain length is suggested to be the consequence of an increasing ordering of the alkane segments which constrains the free aggregation of the phosphonic acid groups. However, the proton mobility is reduced to a greater extent than the proton diffusion coefficient indicating an increasing cooperativity of proton transport with increasing length of the alkane segment. The results clearly indicate that the "spacer concept", which had been proven successful in the optimization of the proton conductivity of heterocycle based systems, fails in the case of phosphonic acid functionalized polymers. Instead, a very high concentration of phosphonic acid functional groups forming "bulky" hydrogen bonded aggregates is suggested to be essential for obtaining very high proton conductivity. Aggregation is also suggested to reduce condensation reactions generally observed in phosphonic acid containing systems. On the basis of this understanding, the proton conductivities of poly(vinyl phosphonic acid) and poly(meta-phenylene phosphonic acid) are discussed. Though both polymers exhibit a substantial concentration of phosphonic acid groups, aggregation seems to be constrained to such an extent that intrinsic proton conductivity is limited to values below sigma = 10(-3) S cm(-1) at T = 150 degrees C. The results suggest that different immobilization concepts have to be developed in order to minimize the conductivity reduction compared to the very high intrinsic proton conductivity of neat phosphonic acid under quasi dry conditions. In the presence of high water activities, however, (as usually present in PEM fuel cells) the very high ion exchange capacities (IEC) possible for phosphonic acid functionalized ionomers (IEC >10 meq g(-1)) may allow for high proton conductivities in the intermediate temperature range (T approximately 120 -160 degrees C).


Subject(s)
Electric Power Supplies/trends , Electrochemistry/methods , Electrolytes/chemistry , Membranes, Artificial , Models, Chemical , Organophosphonates/chemistry , Polymers/chemistry , Computer Simulation , Electric Conductivity , Electrochemistry/trends , Electromagnetic Fields , Temperature
5.
J Endocrinol Invest ; 28(11): 1003-8, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16483179

ABSTRACT

AIM: The aim of this study was to assess the effects of metformin and rosiglitazone on insulin resistance and serum androgen levels in both obese and lean patients with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: Forty lean [body mass index (BMI) < 25 kg/m2] and 40 overweight and obese (BMI > 25 kg/m2) patients were included in the study. Waist and hip measurements, serum sex steroid levels, insulin response to 75-g oral glucose tolerance test, fasting insulin, fasting C-peptide levels and homeostasis model assessment of insulin resistance (HOMA-IR) were determined in all patients. The degree of hirsutism was determined by the Ferriman-Gallwey scoring system. Patients were divided into two groups, with 40 (20 overweight and obese; 20 non-obese) patients each. One group was treated with metformin (MET group) 850 mg bid while the other received rosiglitazone (ROSI group) 4 mg/day for 12 weeks. All measurements were repeated at the end of this period. RESULTS: After the 12-week treatment period, HOMA-IR, area under the curve of insulin, fasting insulin and C-peptide levels were observed to have be decreased significantly in all groups. The decrease in the parameters mentioned above was similar in the four groups. The serum levels of free testosterone, androstenedione and DHEA-S decreased in all groups, but the decrease was statistically significant only in the ROSI groups. Within the lean MET group one patient became pregnant and was hence excluded from the final data analysis. Menstruations became regular after metformin therapy in 41.6% of lean and 35.7% of obese patients who had menstrual disturbance prior to the study. Rosiglitazone therapy improved menstrual disturbance in 61.5 % of lean and 53.8% of obese patients. CONCLUSIONS: Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well. Rosiglitazone seemed to be more effective in decreasing the androgen levels and in achieving slightly greater improvement in menstrual disturbance than metformin.


Subject(s)
Androgens/blood , Hypoglycemic Agents/therapeutic use , Insulin Resistance , Metformin/therapeutic use , Obesity/drug therapy , Polycystic Ovary Syndrome/drug therapy , Thiazolidinediones/therapeutic use , Thinness/drug therapy , Adult , Blood Glucose , Body Mass Index , Fasting , Female , Follicle Stimulating Hormone/blood , Glucose Tolerance Test , Hirsutism/blood , Hirsutism/complications , Hirsutism/drug therapy , Humans , Insulin/blood , Luteinizing Hormone/blood , Menstrual Cycle , Menstruation , Obesity/blood , Obesity/complications , Polycystic Ovary Syndrome/blood , Rosiglitazone , Thinness/blood , Thinness/complications
6.
Hum Reprod ; 19(1): 210-3, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14688184

ABSTRACT

BACKGROUND: Pulsed estrogen therapy is a new approach in estrogen replacement therapy. We carried out a prospective study to evaluate the efficacy of pulsed estrogen therapy in relatively younger patients with surgically induced menopause. METHODS: Patients (n=138) <45 years old and suffering from severe vasomotor symptoms secondary to surgically induced menopause were included in the study. After the initiation of pulsed estrogen therapy (300 microg/day), the patients were re-evaluated every 4 weeks. The dose was increased at each follow-up, if necessary (to a maximum of 600 microg/day). The patients who preferred another method after the first 12 weeks were prescribed oral conjugated estrogen (0.625 mg/day) and at the end of the second 12 weeks their satisfaction levels were assessed. RESULTS: At the end of the first 12 weeks, 26 patients were completely satisfied (18.8%) and 47 were moderately satisfied (34.1%), whereas 65 concluded that the pulsed estrogen therapy they received was ineffective (47.1%). At the end of the second 12 weeks, all the patients were completely satisfied. CONCLUSION: Pulsed estrogen therapy for 12 weeks reduced the frequency of hot flushes in relatively younger patients with surgically induced menopause; however, 81.2% of patients were not completely satisfied at the end of this period.


Subject(s)
Estrogen Replacement Therapy , Estrogens/administration & dosage , Menopause , Estrogen Replacement Therapy/methods , Estrogens/adverse effects , Female , Flushing/drug therapy , Gynecologic Surgical Procedures/adverse effects , Humans , Nebulizers and Vaporizers , Patient Satisfaction , Pulse Therapy, Drug , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...